Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: A randomized controlled trial

Journal of Medical Screening

Volumn 20, Issue 1, 2013, Pages 33-38

  van Leeuwen, Pim J ^a   Kranse, Ries ^b   Hakulinen, Timo ^c   Hugosson, Jonas ^d   Tammela, Teuvo L ^e   Ciatto, Stefano ^f   Roobol, Monique J ^a   Zappa, Marco ^g   De Koning, Harry J ^a   Bangma, Chris H ^a   Moss, Sue M ^h   Auvinen, Anssi ⁱ   Schroder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Integraal Kankercentrum Rotterdam   (Netherlands)

^c FINNISH CANCER REGISTRY   (Finland)

^d SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f Azienda Ospedaliero Universitaria Careggi   (Italy)

^g Institute for Cancer Prevention   (Italy)

^h Cancer Screening Evaluation Unit   (United Kingdom)

ⁱ UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MALE; MASS SCREENING; MIDDLE AGED; MORTALITY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; PROSTATIC NEOPLASMS; BLOOD; EARLY CANCER DIAGNOSIS; EPIDEMIOLOGY; FINLAND; ITALY; NETHERLANDS; SWEDEN;

AGED; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATIC NEOPLASMS; EARLY DETECTION OF CANCER; FINLAND; ITALY; NETHERLANDS; PROSTATE-SPECIFIC ANTIGEN; SWEDEN;

PROSTATE SPECIFIC ANTIGEN;

EID: 84890184068     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1258/jms.2013.012026     Document Type: Article

References (25)

1. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-1328
2. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-732
3. Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981-990
4. De Koning HJ, Blom J, Merkelbach JW, et al. Determining the cause of death in randomized screening trial(s) for prostate cancer. BJU Int 2003;92(Suppl 2):71-78
5. Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 2002;94:167-173
6. Weiss NS, Koepsell TD. Re: All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 2002;94:864-865; author reply 5-6
7. Gail MH, Katki HA. Re: All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 2002;94:862; author reply 5-6
8. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: Final mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1984;2:600-604
9. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788
10. Rogers WJ, Epstein AE, Arciniegas JG, et al. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med 1992;327:227-233
11. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999;340:409-417
12. van Leeuwen PJ, Kranse R, Hakulinen T, et al. Disease-specific mortality may underestimate the total effect of prostate cancer screening. J Med Screen 2010;17:204-210
13. Schroder FH, Denis LJ, Roobol M, et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 2003;92(Suppl. 2):1-13
14. De Koning HJ, Hakulinen T, Moss SM, et al. Monitoring the ERSPC trial. BJU Int 2003;92(Suppl. 2):112-114
15. Hugosson J, Aus G, Bergdahl S, et al. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden. BJU Int 2003;92(Suppl. 2):39-43
16. Finne P, Stenman UH, Maattanen L, et al. The Finnish trial of prostate cancer screening: Where are we now? BJU Int 2003;92(Suppl. 2):22-26
17. Ciatto S, Gervasi G, Frullini P, Zendron P, Zappa M. Specific features of the Italian section of the ERSPC. BJU Int 2003;92(Suppl. 2):30-32
18. Roobol MJ, Schroder FH. European Randomized Study of Screening for Prostate Cancer: Achievements and presentation. BJU Int 2003;92(Suppl. 2):117-122
19. Wolters T, Roobol MJ, Steyerberg EW, et al. The effect of study arm on prostate cancer treatment in a large screening trial (ERSPC). Int J Cancer 2010;126:2387-2393
20. Enderlein G, McCullagh P, Nelder JA. Generalized linear models. Biom J 1987;29:2006-2009
21. Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012;367: 595-560
22. Larsson LG, Nystrom L, Wall S, et al. The Swedish randomised mammography screening trials: Analysis of their effect on the breast cancer related excess mortality. J Med Screen 1996;3:129-132
23. Jonsson H, Tornberg S, Nystrom L, Lenner P. Service screening with mammography of women aged 70-74 years in Sweden. Effects on breast cancer mortality. Cancer Detect Prev 2003;27:360-369
24. Otto SJ, Schroder FH, De Koning HJ. Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: Self-selection bias? J Med Screen 2004;11:89-92
25. Kranse R, Van Leeuwen PJ, Hakulinen T, et al. Excess mortality, attendance matters. J Med Screen 2013.